

6 Literaturverzeichnis

1. Charcot, J., *Histologie de la sclérose en plaque*. Gaz Hop, 1868(41): p. 554-556.
2. Pugliatti, M., S. Sotgiu, and G. Rosati, *The worldwide prevalence of multiple sclerosis*. Clin Neurol Neurosurg, 2002. **104**(3): p. 182-91.
3. Poser, C.M., *The dissemination of multiple sclerosis: a Viking saga? A historical essay*. Ann Neurol, 1994. **36 Suppl 2**: p. S231-43.
4. Kurtzke, J.F., *MS epidemiology world wide. One view of current status*. Acta Neurol Scand Suppl, 1995. **161**: p. 23-33.
5. Kurtzke, J.F., K. Hyllested, and A. Heltberg, *Multiple sclerosis in the Faroe Islands: transmission across four epidemics*. Acta Neurol Scand, 1995. **91**(5): p. 321-5.
6. Poser, C.M., *Notes on the epidemiology of multiple sclerosis*. J Formos Med Assoc, 1995. **94**(6): p. 300-8.
7. Sadovnick, A.D., et al., *A population-based study of multiple sclerosis in twins: update*. Ann Neurol, 1993. **33**(3): p. 281-5.
8. Sadovnick, A.D., *Familial recurrence risks and inheritance of multiple sclerosis*. Curr Opin Neurol Neurosurg, 1993. **6**(2): p. 189-94.
9. Sawcer, S., P.N. Goodfellow, and A. Compston, *The genetic analysis of multiple sclerosis*. Trends Genet, 1997. **13**(6): p. 234-9.
10. Corradu, F., et al., *HLA typing in the United Kingdom multiple sclerosis genome screen*. Neurogenetics, 1998. **2**(1): p. 24-33.
11. Challoner, P.B., et al., *Plaque-associated expression of human herpesvirus 6 in multiple sclerosis*. Proc Natl Acad Sci U S A, 1995. **92**(16): p. 7440-4.
12. Enbom, M., et al., *Similar humoral and cellular immunological reactivities to human herpesvirus 6 in patients with multiple sclerosis and controls*. Clin Diagn Lab Immunol, 1999. **6**(4): p. 545-9.
13. Lassmann, H., et al., *In vivo demyelinating activity of sera from animals with chronic experimental allergic encephalomyelitis. Antibody nature of the demyelinating factor and the role of complement*. J Neurol Sci, 1983. **59**(1): p. 123-37.
14. Wikstrom, J., S. Poser, and G. Ritter, *Optic neuritis as an initial symptom in multiple sclerosis*. Acta Neurol Scand, 1980. **61**(3): p. 178-85.
15. Poser, C.M., et al., *New diagnostic criteria for multiple sclerosis: guidelines for*

- research protocols. *Ann Neurol*, 1983. **13**(3): p. 227-31.
16. McDonald, W.I., et al., *Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis*. *Ann Neurol*, 2001. **50**(1): p. 121-7.
 17. Kurtzke, J.F., *Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)*. *Neurology*, 1983. **33**(11): p. 1444-52.
 18. Rudick, R.A., et al., *Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS*. *Neurology*, 2001. **56**(10): p. 1324-30.
 19. Milligan, N.M., R. Newcombe, and D.A. Compston, *A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects*. *J Neurol Neurosurg Psychiatry*, 1987. **50**(5): p. 511-6.
 20. Compston, D.A., et al., *A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results*. *J Neurol Neurosurg Psychiatry*, 1987. **50**(5): p. 517-22.
 21. Arnason, B.G., *Treatment of multiple sclerosis with interferon beta*. *Biomed Pharmacother*, 1999. **53**(8): p. 344-50.
 22. Hartung, H.P. and B.C. Kieseier, *Targets for the therapeutic action of interferon-beta in multiple sclerosis*. *Ann Neurol*, 1996. **40**(6): p. 825-6.
 23. Johnson, K.P., et al., *Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial*. *The Copolymer 1 Multiple Sclerosis Study Group*. *Neurology*, 1995. **45**(7): p. 1268-76.
 24. Bloch, F., Hansen W W, Packard M E, *Nuclear induction*. *Physiol Rev.*, 1946(69): p. 127-128.
 25. Purcell, E.M., *Resonance absorption by nuclear magnetic moments in a solid*. *Physiol Rev.*, 1946(64): p. 37-38.
 26. Lauterbur, P.C., *Image formation by induced local interactions: examples employing nuclear magnetic resonance*. *Nature*, 1973(242): p. 190-191.
 27. Jackson, J.A., et al., *Magnetic resonance imaging in multiple sclerosis: results in 32 cases*. *AJNR Am J Neuroradiol*, 1985. **6**(2): p. 171-6.
 28. Loevner, L.A., et al., *Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis: assessment with magnetization-transfer measurements*. *Radiology*, 1995. **196**(2): p. 511-5.
 29. van Buchem, M.A., et al., *Quantitative volumetric magnetization transfer*

- analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden.* Magn Reson Med, 1996. **36**(4): p. 632-6.
30. De Stefano, N., et al., *Chemical pathology of acute demyelinating lesions and its correlation with disability.* Ann Neurol, 1995. **38**(6): p. 901-9.
 31. Moffett, J.R., et al., *Immunohistochemical localization of N-acetylaspartate in rat brain.* Neuroreport, 1991. **2**(3): p. 131-4.
 32. Arnold, D.L., et al., *Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease.* Magn Reson Med, 1990. **14**(1): p. 154-9.
 33. Bruhn, H., et al., *Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo.* Ann Neurol, 1992. **32**(2): p. 140-50.
 34. Larsson, H.B., et al., *In vivo magnetic resonance diffusion measurement in the brain of patients with multiple sclerosis.* Magn Reson Imaging, 1992. **10**(1): p. 7-12.
 35. Matthews, P.M., et al., *Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis.* Semin Neurol, 1998. **18**(3): p. 327-36.
 36. Fu, L., et al., *Imaging axonal damage of normal-appearing white matter in multiple sclerosis.* Brain, 1998. **121** (Pt 1): p. 103-13.
 37. Narayanan, S., et al., *Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter.* Neuroimage, 2006. **29**(2): p. 637-42.
 38. Tartaglia, M.C., et al., *Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis.* J Neurol, 2002. **249**(10): p. 1382-90.
 39. Vrenken, H., et al., *MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter.* Magn Reson Med, 2005. **53**(2): p. 256-66.
 40. Forsen, F., Hoffmann, RA, *Study of moderately rapid chemical exchange reaction by means of nuclear magnetic double resonance.* Journal Chem Phys, 1963(39): p. 2892-2901.
 41. Wolff, S.D. and R.S. Balaban, *Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo.* Magn Reson Med, 1989. **10**(1): p. 135-44.

42. Balaban, R.S. and T.L. Ceckler, *Magnetization transfer contrast in magnetic resonance imaging*. Magn Reson Q, 1992. **8**(2): p. 116-37.
43. Wolff, S.D. and R.S. Balaban, *Magnetization transfer imaging: practical aspects and clinical applications*. Radiology, 1994. **192**(3): p. 593-9.
44. Petrella, J.R., et al., *Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect*. AJNR Am J Neuroradiol, 1996. **17**(6): p. 1041-9.
45. Finelli, D.A., et al., *Improved contrast of enhancing brain lesions on postgadolinium, T1-weighted spin-echo images with use of magnetization transfer*. Radiology, 1994. **190**(2): p. 553-9.
46. Mehta, R.C., G.B. Pike, and D.R. Enzmann, *Improved detection of enhancing and nonenhancing lesions of multiple sclerosis with magnetization transfer*. AJNR Am J Neuroradiol, 1995. **16**(9): p. 1771-8.
47. van Waesberghe, J.H., *Magnetization transfer ratios and contrast in multiple sclerosis*. Advances in MRI Contrast, 1996(4): p. 54-60.
48. Dousset, V., et al., *Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging*. Radiology, 1992. **182**(2): p. 483-91.
49. Kimura, H., et al., *Magnetization transfer imaging of diffuse axonal injury following experimental brain injury in the pig: characterization by magnetization transfer ratio with histopathologic correlation*. J Comput Assist Tomogr, 1996. **20**(4): p. 540-6.
50. Lexa, F.J., R.I. Grossman, and A.C. Rosenquist, *Dyke Award paper. MR of wallerian degeneration in the feline visual system: characterization by magnetization transfer rate with histopathologic correlation*. AJNR Am J Neuroradiol, 1994. **15**(2): p. 201-12.
51. Newcombe, J., M.N. Woodroffe, and M.L. Cuzner, *Distribution of glial fibrillary acidic protein in gliosed human white matter*. J Neurochem, 1986. **47**(6): p. 1713-9.
52. Allen, I.V. and S.R. McKeown, *A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis*. J Neurol Sci, 1979. **41**(1): p. 81-91.
53. Trapp, B.D., et al., *Axonal transection in the lesions of multiple sclerosis*. N Engl J Med, 1998. **338**(5): p. 278-85.
54. van Waesberghe, J.H., et al., *Axonal loss in multiple sclerosis lesions: magnetic*

- resonance imaging insights into substrates of disability*. Ann Neurol, 1999. **46**(5): p. 747-54.
55. Trapp, B.D., et al., *Pathogenesis of tissue injury in MS lesions*. J Neuroimmunol, 1999. **98**(1): p. 49-56.
 56. Silver, N.C., G.J. Barker, and D.H. Miller, *Standardization of magnetization transfer imaging for multicenter studies*. Neurology, 1999. **53**(5 Suppl 3): p. S33-9.
 57. van Buchem, M.A. and P.S. Tofts, *Magnetization transfer imaging*. Neuroimaging Clin N Am, 2000. **10**(4): p. 771-88,ix.
 58. Filippi, M., et al., *Semi-automated thresholding technique for measuring lesion volumes in multiple sclerosis: effects of the change of the threshold on the computed lesion loads*. Acta Neurol Scand, 1996. **93**(1): p. 30-4.
 59. Ashton, E.A., et al., *Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRI*. J Magn Reson Imaging, 2003. **17**(3): p. 300-8.
 60. Richert, N.D. and J.A. Frank, *Magnetization transfer imaging to monitor clinical trials in multiple sclerosis*. Neurology, 1999. **53**(5 Suppl 3): p. S29-32.
 61. Charil, A., et al., *Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets*. Neuroimage, 2003. **19**(3): p. 532-44.
 62. Cutter, G.R., et al., *Development of a multiple sclerosis functional composite as a clinical trial outcome measure*. Brain, 1999. **122** (Pt 5): p. 871-82.
 63. Rovaris, M., et al., *Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis*. AJNR Am J Neuroradiol, 2000. **21**(2): p. 402-8.
 64. Rudick, R.A., G. Cutter, and S. Reingold, *The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials*. Mult Scler, 2002. **8**(5): p. 359-65.
 65. Rovaris, M., et al., *Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis*. Neurology, 1998. **50**(6): p. 1601-8.
 66. Kalkers, N.F., et al., *Optimizing the association between disability and biological markers in MS*. Neurology, 2001. **57**(7): p. 1253-8.
 67. Barkhof, F., *MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS)*. Mult Scler, 1999. **5**(4): p. 283-6.

68. van der Valk, P. and C.J. De Groot, *Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS*. *Neuropathol Appl Neurobiol*, 2000. **26**(1): p. 2-10.
69. De Groot, C.J., et al., *Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions*. *Brain*, 2001. **124**(Pt 8): p. 1635-45.
70. Leary, S.M., et al., *Magnetisation transfer of normal appearing white matter in primary progressive multiple sclerosis*. *Mult Scler*, 1999. **5**(5): p. 313-6.
71. Hiehle, J.F., Jr., et al., *Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis*. *Magn Reson Med*, 1994. **32**(3): p. 285-93.
72. Narayanan, S., et al., *Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b*. *J Neurol*, 2001. **248**(11): p. 979-86.
73. Parry, A., et al., *Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis*. *J Neurol*, 2003. **250**(2): p. 171-8.
74. Laule, C., et al., *Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis*. *J Neurol*, 2003. **250**(8): p. 924-31.
75. Patel, U.J., et al., *Serial analysis of magnetization-transfer histograms and Expanded Disability Status Scale scores in patients with relapsing-remitting multiple sclerosis*. *AJNR Am J Neuroradiol*, 1999. **20**(10): p. 1946-50.
76. Filippi, M., et al., *Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging*. *Magn Reson Imaging*, 1999. **17**(7): p. 979-84.
77. Filippi, M., et al., *Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium*. *Neurology*, 1998. **50**(5): p. 1289-93.
78. Filippi, M., et al., *Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study*. *Neurology*, 2000. **55**(7): p. 940-6.
79. Goodkin, D.E., et al., *A serial study of new MS lesions and the white matter from which they arise*. *Neurology*, 1998. **51**(6): p. 1689-97.
80. Campi, A., et al., *Magnetisation transfer ratios of contrast-enhancing and nonenhancing lesions in multiple sclerosis*. *Neuroradiology*, 1996. **38**(2): p. 115-9.
81. Dousset, V., et al., *Early structural changes in acute MS lesions assessed by*

- serial magnetization transfer studies*. Neurology, 1998. **51**(4): p. 1150-5.
82. Kita, M., et al., *Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a*. Neurology, 2000. **54**(9): p. 1741-5.
83. Inglese, M., et al., *The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS*. Neurology, 2003. **60**(5): p. 853-60.
84. Richert, N.D., et al., *Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b*. AJNR Am J Neuroradiol, 1998. **19**(9): p. 1705-13.
85. Richert, N.D., et al., *Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis*. Mult Scler, 2001. **7**(1): p. 49-58.
86. Yong, V.W., *Differential mechanisms of action of interferon-beta and glatiramer acetate in MS*. Neurology, 2002. **59**(6): p. 802-8.
87. Yong, V.W., et al., *Interferon beta in the treatment of multiple sclerosis: mechanisms of action*. Neurology, 1998. **51**(3): p. 682-9.
88. Filippi, M., et al., *Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial*. Lancet, 2004. **364**(9444): p. 1489-96.
89. Molyneux, P.D., et al., *The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis*. Brain, 2000. **123** (Pt 11): p. 2256-63.
90. Liu, Z., et al., *Immunomodulatory effects of interferon beta-1a in multiple sclerosis*. J Neuroimmunol, 2001. **112**(1-2): p. 153-62.
91. Barkhof, F., et al., *Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance*. Arch Neurol, 2003. **60**(8): p. 1073-81.
92. Cohen, J.A., et al., *Benefit of interferon beta-1a on MSFC progression in secondary progressive MS*. Neurology, 2002. **59**(5): p. 679-87.
93. Fischer, J.S., et al., *Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group*. Ann Neurol, 2000. **48**(6): p. 885-92.